Merck KGaA Backs Mid-Term Targets; Plans Acquisitions as of 2023
06 Octubre 2022 - 1:55AM
Noticias Dow Jones
By Cecilia Butini
Merck KGaA on Thursday backed its medium-term targets at group
level and for its business units, and said that it plans further
in-licensing deals and acquisitions as of next year.
The German pharmaceuticals-and-chemicals company said it remains
on track to reach its growth target of 25 billion euros ($24.71
billion) in sales by 2025. Sales growth is expected at an average
of 6% a year, which equates to an increase of more than EUR1
billion annually, the company said.
Merck backed a mid-term forecast at both group and divisional
levels and said it continues to expect sales growth to progress in
its life science, healthcare and electronics business.
"As of 2023, the group will once again consider potential
larger-scale acquisitions as an option," Merck said, adding that it
plans both bolt-on acquisitions and in-licensing deals.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
October 06, 2022 02:40 ET (06:40 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Merck KGaA (PK) (USOTC:MKKGY)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Merck KGaA (PK) (USOTC:MKKGY)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Merck KGaA (PK) (OTCMarkets): 0 recent articles
Más de Merck KGaA (PK) Artículos de Noticias